Description:

CALGB 40503 FOLLOW-UP SOLID TUMOR EVALUATION FORM NCT00601900 Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=2403CF57-F8CB-54C8-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=2403CF57-F8CB-54C8-E044-0003BA3F9857

Keywords:
Versions (3) ▾
  1. 8/26/12
  2. 1/8/15
  3. 6/3/15
Uploaded on:

June 3, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

CALGB 40503 FOLLOW-UP SOLID TUMOR EVALUATION FORM NCT00601900

INSTRUCTIONS: Complete and submit this form as required by the protocol. Information in the upper right box must be completed for this form to be accepted. For optimal accuracy use black ink.

Header
Are data amended
Reporting Period
Target Lesion Site
Method of Evaluation (**)
cm
Response Status at This Assessment, Target Lesion (s)
Non-target Lesion(s) Follow-up Evaluation
Nontarget Lesion
Nontarget Lesion Site
F/U Response Status (Use response status codes below.)
Response Status at This Assessment, Non-Target Lesion (s)
New Lesion(s) At Follow-up Evaluation
Was the appearance of any new lesions documented
Were any of the new lesion(s) in a previously reported anatomic site
Was the lesion in a new anatomic site
Lesion in previously reported site
New Lesion Site
Target Lesion
Overall Response

Similar models